

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|-----------|--|
| (51) International Patent Classification ⁶ : A61L 25/00, 27/00, A61K 6/033 | A1 | (11) International Publication Number: WO 95/13835 (43) International Publication Date: 26 May 1995 (26.05.95) |
| (21) International Application Number: PCT/US93/11071 (22) International Filing Date: 15 November 1993 (15.11.93) (71)(72) Applicants and Inventors: LIU, Sung-Tsuen [US/US]; 29 Landing, Laguna Niguel, CA 92677 (US). CHUNG, Harvey, H. [US/US]; 43 Via Costa Verde, Rancho Palos Verdes, CA 90274 (US). (74) Agents: McCLAIN, James, W. et al.; Brown, Martin, Haller & McClain, Suite 1300, 110 West "C" Street, San Diego, CA 92101 (US). | | (81) Designated States: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> |
| (54) Title: RESORBABLE BIOACTIVE PHOSPHATE CONTAINING CEMENTS (57) Abstract A surgical cement of high biocompatibility, useful in orthopedic, maxillofacial and dental applications, comprising a calcium alkali phosphate cement with relatively high surface pH of about 7 or higher, and having a wide variety of chemical compositions, permitting flexibility in controlling the bioresorption rate by changing the chemical composition of the cementing powder. | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria | GB | United Kingdom | MR | Mauritania |
| AU | Australia | GE | Georgia | MW | Malawi |
| BB | Barbados | GN | Guinea | NE | Niger |
| BE | Belgium | GR | Greece | NL | Netherlands |
| BF | Burkina Faso | HU | Hungary | NO | Norway |
| BG | Bulgaria | IE | Ireland | NZ | New Zealand |
| BJ | Benin | IT | Italy | PL | Poland |
| BR | Brazil | JP | Japan | PT | Portugal |
| BY | Belarus | KE | Kenya | RO | Romania |
| CA | Canada | KG | Kyrgyzstan | RU | Russian Federation |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan |
| CG | Congo | KR | Republic of Korea | SE | Sweden |
| CH | Switzerland | KZ | Kazakhstan | SI | Slovenia |
| CI | Côte d'Ivoire | LI | Liechtenstein | SK | Slovakia |
| CM | Cameroon | LK | Sri Lanka | SN | Senegal |
| CN | China | LU | Luxembourg | TD | Chad |
| CS | Czechoslovakia | LV | Latvia | TG | Togo |
| CZ | Czech Republic | MC | Monaco | TJ | Tajikistan |
| DE | Germany | MD | Republic of Moldova | TT | Trinidad and Tobago |
| DK | Denmark | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | US | United States of America |
| FI | Finland | MN | Mongolia | UZ | Uzbekistan |
| FR | France | | | VN | Viet Nam |
| GA | Gabon | | | | |

RESORBABLE BIOACTIVE PHOSPHATE CONTAINING CEMENTS**BACKGROUND OF THE INVENTION****1. Field of the Invention**

This invention relates to a surgical cement, also known as bone
5 cement or bioresorbable implantation material, and its process of formation.
The cements of this invention are formed from calcium alkali phosphate
ceramics and acidic citrate setting reagents, which when combined with an
aqueous solution form a moldable paste having high biocompatibility. The
paste is easy to manipulate and reaches neutral pH or higher shortly after
10 hardening. The resulting cements are useful in orthopedic and maxillofacial
surgeries and in dental applications.

2. Description of the Prior Art

In the last two decades, many artificial hard tissue implant materials
have been made. since the Major inorganic component of human hard tissue
15 (e.g. bone, teeth) is a calcium phosphate compound, which is biological
apatite, hydroxy-apatite and other calcium phosphate ceramics were
logically selected for hard tissue implant materials.

Most of the previous calcium phosphate cements developed used
hydroxyapatite or tricalcium phosphate as the cementing ceramic and
20 phosphoric acid, bifunctional organic acids or other polyfunctional organic
acids as setting reagents. These cements are normally very acidic in nature
and take a very long time to reach neutral pH. After implantation, these
cements may cause irritation and inflammatory reactions.

Biocompatibility has been the limiting factor in successful applications
25 of implant materials. The most successful artificial implant materials to

achieve the excellent biocompatibility have been hydroxyapatite, bioglass¹, and other calcium phosphate ceramics. Hydroxyapatite and β -tricalcium phosphate ceramics and calcium phosphate containing glass have been extensively studied. Clinical studies confirmed that most of the calcium phosphate ceramics such as hydroxyapatite, tricalcium phosphate, tetracalcium phosphate and dicalcium phosphate have excellent biocompatibility and are well accepted by both hard tissue and soft tissue. The experimental results also indicated that dense hydroxyapatite is non-bioresorbable while other porous calcium phosphate ceramics are bioresorbable.

The surgeon is most interested in implant materials that can be shaped and harden *in situ*, but such bioceramic preparations are not yet available. Most of the calcium phosphate ceramics for medical applications are prepared either in granule form or block form. The granule form has poor manipulation characteristics while the block form is very brittle and difficult to shape. In order to solve the above problems, many attempts have been made to prepare binder systems for bioceramics. Plaster of Paris, collagen, polylactate, polyacrylate, calcium phosphate grout and hydroxyapatite cement have been used.

Ideally, a useful binder system for bioceramics should have good biocompatibility, (including a near neutral pH), a suitable bioresorption rate, be moldable at surgical sites, and have good setting characteristics. The acidity of the setting cement is dependent on the type of calcium phosphate

¹ A bioactive glass material whose major components are CaO, SiO₂ and P₂O₅. Minor components may be Na₂O, MgO, Al₂O₃, B₂O₃ and CaF₂. A bioactive glass can form a surface layer of hydroxyapatite when soaked in the aqueous environment.

salt used, the acidity of the setting reagent, and the reaction rate. Typical cements are formed from dissolution and recrystallization of salts with Ca/P mole ratio > 1 after combination with acidic reagents.

When the calcium phosphate salt reacts with the acid setting reagent
5 to form a cement, the calcium phosphate dissolves and new calcium compounds are formed during the setting stage. The extent of the reaction, the setting time and setting characteristics are sensitive to the nature of calcium phosphate powder, the pH and the type of setting reagents. Even when excess calcium phosphate powder is used to form a paste with highly
10 soluble acidic setting reagent, the setting cement will nevertheless contain some unreacted acid setting reagent trapped in the cement. The result is low surface pH of the setting cement. If the calcium phosphate cementing powder is near neutral and has a very slow dissolution rate, the surface pH will stay low for a long time. This low pH cement is undesirable since it
15 may cause irritation and inflammatory reactions. Additionally setting times of this cement are difficult to control and it has poor manipulation characteristics.

Most binders have disadvantages. Plaster of Paris has a reasonable setting characteristics but the resorption rate is too fast. Collagen-
20 hydroxyapatite composites and polylactatehydroxyapatite can serve as a useful delivery system for hydroxyapatite or other calcium phosphate granular ceramics, but these composite materials must be premolded; they cannot be molded at the surgical site.

Calcium phosphate grout does not set well in the *in situ* aqueous
25 environment. For example, a recently reported calcium phosphate cement

combined with bifunctional acids as setting reagents (U.S. patent 4,668,295) was very acidic, disintegrated very fast in the *in situ* aqueous environment, and lacked good setting characteristics. Pure hydroxyapatite cement prepared by reacting tetracalcium phosphate and other calcium phosphates is not resorbable and does not have good setting characteristics (U.S. patents 4,518,430 and 4,612,053).

Oonishi² reported a bioactive α -tricalcium phosphate cement. This calcium phosphate cement has a reasonable setting time and strong mechanical strength, but is very acidic. More recently, a bioglass cement containing calcium phosphate using phosphoric acid or calcium hydroxide as the setting reagent has been reported.³ The bioglass cement with phosphoric acid has low pH. No setting characteristic of this bioglass cement has been reported.

15

SUMMARY OF THE INVENTION

This invention relates to surgical cements formed by combining calcium alkali phosphate ceramics with acidic citrate setting reagents which shortly after setting have near neutral surface pH (pH 7) and are highly biocompatible, moldable, and resorbable. Since the material of this invention may be mixed to vary the reaction rates, greater flexibility of use may be expected because the medical technician could apply this invention in paste form *in situ* or premold the implant.

² H. Oonishi, et al., "Studies on Development of α -TCP Bioactive Bone Cement" Posted Paper, Engineering Foundation Conferences, Bioceramics, Santa Barbara, CA 1986.

³ W.S. Chen, Y. Chen, J.P. Rausch, E.A. Monroe, "Phosphate Glass Bone Graft", page 241, The 15th Annual Meeting of the Society for Biomaterials, april 28-May 2, 1989, Lake Buena Vista, FL.

The present invention uses a highly alkaline and rapidly dissolving calcium alkali phosphate ceramic, such as calcium sodium phosphate or calcium potassium phosphate ceramics which result in the increased surface pH of the surgical cement and hence the greater biocompatibility.

5 Additionally, the present invention provides increased bioresorption and improved manipulation characteristics. This invention permits manipulation of the cementitious paste at the surgical site for hard tissue replacement within a reasonable setting time. It can also be prepared in premolded shapes.

10 Resorption rates can be varied by predetermined mixtures of biocompatible filler compounds added to the cementing powders. These cements are only slightly acidic after mixing into a paste. After setting in the liquid environment, the surface pH of the cements raises rapidly to near 7 or higher.

15 In summary, the advantages of these cements are relatively high surface pH, good biocompatibility, bioresorbability, reasonable setting time and good manipulation characteristics. Consequently, these cements have greater usefulness as implants for hard tissue replacement materials over prior art. They can be used for bone graft, bone fracture fixation, bone
20 defect fillers, maxillofacial surgery, spinal fusion, bone cements, dental cements and drug delivery systems. They can also be used as a binder system for the granule form of calcium phosphate ceramics.

///

///

25 ///

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Among the pure calcium phosphate salts, only tetracalcium phosphate
5 is alkaline in nature. In a preparation of calcined phosphate fertilizer, Ando⁴
and Ando and Matsuno⁵ reported the formation of mixed ceramics. This
mixed ceramic is a crystalline solid solution containing tricalcium phosphate,
 $\text{Ca}_5\text{Na}_2(\text{PO}_4)_4$ and rhenantite (α and β form of CaNaPO_4). In general, these
calcium sodium phosphate ceramics are alkaline in nature, and have
10 relatively high solubility. Similarly, the calcium potassium phosphate
ceramics are also alkaline and have high dissolution rates. The present
invention uses these calcium alkali containing phosphate ceramics for the
cementing powder. Because of the alkaline nature and high dissolution
rates, these ceramics are able to react with acidic citrate compounds
15 yielding cements with relatively short setting times ranging from several
minutes to about a half an hour, and having high surface pH.

The setting reagents used in this invention are acidic citrate
compounds, including citric acid, dihydrogen citrate salts or monohydrogen
citrate salts. In the present cement system, the weight ratio of cementing
20 powder to setting reagent varies from 1.2:1 to 10:1. When the ratio is as
high as 10, the final set cement contains reaction products and high
amounts of bioresorbable unreacted calcium alkali phosphate.

A further increase of the surface pH of the setting cement may be
achieved by using hydrogen citrate salts or citric acid with alkaline reagents

⁴ J. Ando, "Phase Diagrams of $\text{Ca}_3(\text{PO}_4)_2$ - $\text{Mg}_3(\text{PO}_4)_2$ and $\text{Ca}_3(\text{PO}_4)_2$ - CaNaPO_4 Systems", Bull. Chem. Soc., Japan, 31, 201 (1958).

⁵ J. Ando and S. Matsuno, " $\text{Ca}_3(\text{PO}_4)_2$ - CaNaPO_4 System," Bull. Chem. Soc., Japan, 41, 342 (1968).

instead of using pure citric acid as the setting reagent. Among the suitable hydrogen citrate salts are: sodium dihydrogen citrate, disodium hydrogen citrate, ammonium dihydrogen citrate, diammonium hydrogen citrate, potassium dihydrogen citrate and dipotassium hydrogen citrate. The pH
5 may also be raised by using citric acid with alkaline reagents. Suitable alkaline reagents include NaOH, KOH, KH_2OH , sodium citrate, potassium citrate, ammonium citrate, sodium phosphate, disodium hydrogen phosphate, potassium phosphate, and dipotassium hydrogen phosphate. While the pH of concentrated pure citric acid is normally at 2, the pH
10 modified setting reagent should provide an initial solution pH which is much higher than the pure citric acid, reaching a pH of 3 to 5. Therefore, after setting, the surface pH of the setting cement will initially be near 5 and quickly reach 7 or higher upon hardening.

The surgical cement of this invention relates to a flexible composition
15 by changing the $\text{CaO}:\text{Na}_2\text{O}$ or $\text{CaO}:\text{K}_2\text{O}$ mole ratios in the calcium alkali phosphate ceramics. The dissolution rate as well as the bioresorption rate of the cement changes accordingly. The overall chemical composition of these ceramics can be changed from $2.9 \text{ CaO}-0.1 \text{ Na}_2\text{O}\cdot\text{P}_2\text{O}_5$ to $0.8 \text{ CaO}-2.2 \text{ Na}_2\text{O}\cdot\text{P}_2\text{O}_5$. The calcium potassium phosphate ceramics can be varied
20 in composition in the same manner. While these mixed ceramics cover a wide variety of chemical compositions and a wide range of dissolution rates, in general, the dissolution rates increase by increasing the alkali element content. As a result, the technician can achieve greater bioresorption rate control with the mixed ceramics than with the pure single component
25 calcium phosphate cements.

Further control of the bioresorption rate in this invention is achieved by incorporating a biocompatible filler material in the form of fine powder or granule, having a particle size ranging from a few microns to 20 mesh. Filler material must be biocompatible without significantly effecting the integrity and setting behavior of the cement. Fillers useful for this purpose include tetracalcium phosphate, tricalcium phosphate, calcium phosphate apatite, dicalcium phosphate, calcium carbonate, calcium sulfate dehydrate, calcium sulfate hemihydrate, calcium sulfate anhydrous, calcium fluoride, calcium oxide, calcium hydroxide, calcium citrate, magnesium hydroxide, magnesium oxide, collagen and other sparingly calcium organic salts. The weight ratio of filler to calcium alkali phosphate cementing powder can be up to 5:1.

In the present invention the cementing powder was premixed with filler material to form a homogeneous mixed powder. The setting reaction can be initiated either by dissolving the setting reagent and pH adjustment reagents in water or saline water to form an aqueous setting solution and adding it to the premixed powder, or premixing the solid setting reagents with the cementing powder and using sterilized pure water or saline water as the setting aqueous solution.

The cements of the present invention may be used as implant materials for: (1) bone grafts as filler or replacement of bone that has been removed surgically or traumatically; (2) ridge augmentations; (3) jaw repairs; (4) cranial and maxillofacial surgeries; (5) luting cement in dentistry and orthopedic surgery; (6) spinal fusions; (7) endodontic applications; (8) root cements; (9) replacing or promoting regeneration of bone mineral lost due to periodontal disease; and (10) drug release systems. Antibiotics (up to

20% of cement by weight) and bone growth proteins (up to 10% of cement by weight) are the preferred drugs to be released by the cement of this invention.

The strength as well as the setting time of the present cements are
5 directly dependent on the nature and particle size of the calcium alkali phosphate ceramics, the nature of the filler powder, the type and amount of the setting reagent, and the solid powder to liquid ratio. In general, with other factors constant, the strength increases as the particle size of the powder decreases. The setting time increases as the cementing powder to
10 setting reagent weight ratio decreases.

The cement can be molded to any shape before use. For example, when used as a drug delivery system, the required amount of the drug is mixed with the cementing powder and setting reagent to form paste first. After setting, the hardened cement may be broken into a suitably sized
15 granules. This drug containing cement is then dried and stored before use. For more convenient applications at the surgical site, the cement can then be prepared as a paste first. The paste can be introduced into the bone defects or implantation site before it becomes hardened.

This invention may be prepared as a kit, comprising a selected
20 cementing powder and setting reagent which when admixed with aqueous solution will form a paste. This paste will harden in a short time and will reach a pH near 7 or higher.

EXAMPLE 1

25 Pure CaNaPO_4 (calcium sodium phosphate) ceramic was prepared by

solid state reaction at high temperature. Stoichiometric amounts of CaHPO_4 and Na_2CO_3 corresponding to the formation of CaNaPO_4 were homogeneously mixed. The mixed powder was then sintered at high temperature to form CaNaPO_4 ceramic. The ceramic was then ground to fine powder. 2 g of the CaNaPO_4 powder was mixed with 0.8 g of solid citric acid. A few drops of pure water was then added to form a sticky paste. After mixing, the paste set within several minutes. Shortly after setting, the surface pH of the set cement was tested with pH indicator paper. Initially, the surface pH was near 5; it reached 7 or higher in less than a half hour. The hardened cement aged in pure water did not show any sign of disintegration.

EXAMPLE 2

2 g of CaNaPO_4 fine ceramic powder prepared from Example 1 was premixed with 0.3 g of citric acid and 0.3 g of trisodium citrate. The premixed powder was then mixed with few drops of pure water to form a homogeneous paste. This paste set in a few minutes. After setting, the initial surface pH was near 6 and reached 7 or higher in less than half hour.

20 EXAMPLE 3

CaNaPO_4 mixed ceramics having an overall chemical composition of $2.7 \text{ CaO} \cdot 0.3 \text{ Na}_2\text{O} \cdot \text{P}_2\text{O}_5$ were prepared by solid state reaction at high temperatures. Required amounts of CaHPO_4 , Na_2CO_3 and CaCO_3 were mixed homogeneously and sintered. After sintering, the prepared mixed ceramics were ground to fine powder, and 2 g of the prepared ceramics

powder was mixed with 0.6 g of anhydrous citric acid. This mixed powder was then mixed with few drops of 10% saline water. The paste hardened within five minutes. The set cement had a surface pH near 5. The surface pH reached to near 7 within less than half hour after setting.

5

EXAMPLE 4

CaNaPO₄ pure ceramic was prepared by solid reaction at high temperatures. Required amounts of (NH₄)₂HPO₄, Na₂CO₃ and CaCO₃ were mixed homogeneously and sintered. The sintered ceramic has the same
10 x-ray pattern as those prepared from Example 1. The sintered solid was then ground to fine powder. 1.5 g of anhydrous citric acid and 1.5 g of trisodium citrate was dissolved in 5 ml of pure water to form the setting solution. 1 g of prepared CaNaPO₄ ceramic powder was mixed with 1 g of anhydrous calcium sulfate. This mixed powder was then mixed with a few
15 drops of the setting solution to form a paste which set in a few minutes. The surface pH was near 6 at the beginning, and increased to 7 or higher within a half hour after setting. No signs of surface disintegration were shown after soaking the set cement in pure water.

20 EXAMPLE 5

Mixed ceramics of CaNaPO₄ with the chemical composition of 1.2 CaO•1.8 Na₂O•P₂O₅ were prepared by solid state reaction at high temperatures. Required amounts of (NH₄)₂HPO₄, CaCO₃ and Na₂CO₃ corresponding to the above chemical composition were mixed
25 homogeneously and sintered. The sintered ceramic was then ground to fine

powder. This prepared ceramic has high alkalinity and dissolves much faster than other calcium ceramics. 2 g of the above prepared ceramic fine powder was mixed with 0.4 g of anhydrous citric acid and 0.4 g of trisodium citrate. This mixed powder was then mixed with few drops of
5 pure water to form a paste. The surface pH of the set cement was near 7.

Examples 1-5 use calcium and sodium phosphate ceramics, but calcium potassium phosphate ceramics can be used interchangeably with the calcium sodium phosphate ceramics and, thus, also react with citric acid or acidic citrate salts to form biocompatible and resorbable cements. It
10 should be understood that the foregoing disclosure emphasizes certain embodiments of the invention and that all modifications or alternatives thereto are within the spirit and scope of the invention.

CLAIMS

1. A surgical cement for orthopedic, dental, and maxillofacial applications comprising:

a cementing powder selected from the group of calcium alkali phosphate ceramics consisting of calcium sodium phosphate or calcium
5 potassium phosphate ceramics;

a setting reagent selected from the group of acidic citrates consisting of citric acid or acidic citrate salts wherein the weight ratio of cementing powder to setting reagent lies between 1.2:1 and 10:1, and

sufficient aqueous setting solution selected from the group
10 consisting of sterilized pure water and saline water to form a cementitious paste, said paste reaching a neutral pH of 7 shortly after setting.

2. The surgical cement of claim 1 wherein the cementing powder is selected from the group consisting of CaNaPO_4 or $\text{Ca}_5\text{Na}_2(\text{PO}_4)_4$.

3. The surgical cement of claim 1 wherein the cementing powder selected from the group of calcium alkali phosphate ceramics consists of mixed ceramics as a crystalline solution containing $\text{Ca}_3(\text{PO}_4)_2$, CaNaPO_4 and $\text{Ca}_5\text{Na}_2(\text{PO}_4)_4$, and has an overall chemical composition ranging from
5 $2.9 \text{ CaO} \cdot 0.1 \text{ Na}_2\text{O} \cdot \text{P}_2\text{O}_5$ to $2.0 \text{ CaO} \cdot \text{Na}_2\text{O} \cdot \text{P}_2\text{O}_5$ prepared from solid state reaction at high temperatures.

///

4. The surgical cement of claim 1 wherein the calcium alkali phosphate ceramic further comprises mixed ceramics of CaNaPO_4 and Na_3PO_4 having an overall chemical composition ranging from $2.0 \text{ CaO} \cdot \text{Na}_2\text{O} \cdot \text{P}_2\text{O}_5$ to $0.8 \text{ CaO} \cdot 2.2 \text{ Na}_2\text{O} \cdot \text{P}_2\text{O}_5$ prepared from solid state
5 reaction at high temperatures.

5. The surgical cement of claim 1 wherein the calcium alkali phosphate ceramic comprises CaKPO_4 .

6. The surgical cement of claim 1 wherein the calcium alkali phosphate ceramic is a mixed ceramic as a crystalline solution of $\text{Ca}_3(\text{PO}_4)_2$ and CaKPO_4 , and has an overall chemical composition ranging from $2.9 \text{ CaO} \cdot 0.1 \text{ K}_2\text{O} \cdot \text{P}_2\text{O}_5$ to $2.0 \text{ CaO} \cdot 1.0 \text{ K}_2\text{O} \cdot \text{P}_2\text{O}_5$ prepared from solid state
5 reaction at high temperatures.

7. The surgical cement of claim 1 wherein the calcium alkali phosphate ceramic further comprises a mixed ceramic of CaKPO_4 and K_3PO_4 having an overall chemical composition ranging from $2.0 \text{ CaO} \cdot \text{K}_2\text{O} \cdot \text{P}_2\text{O}_5$ to $0.8 \text{ CaO} \cdot 2.2 \text{ K}_2\text{O} \cdot \text{P}_2\text{O}_5$ prepared from solid state reaction at high
5 temperatures.

8. The surgical cement of claim 1 wherein the setting reagent selected from the group of acidic citrates comprises citric acid and at least one of the following citrate compounds: NaH_2 citrate, Na_2H citrate, KH_2 citrate, K_2H citrate, NH_4H_2 citrate, and $(\text{NH}_4)_2\text{H}$ citrate.

9. The surgical cement of claim 1 further including a soluble pH adjusting reagent.

10. The surgical cement of claim 9 wherein said soluble pH adjusting reagents are selected from the group consisting of: NaOH, KOH, NH_4OH , Na_3 citrate, K_3 citrate, $(\text{NH}_4)_3$ citrate, Na_3PO_4 , Na_2HPO_4 , K_3PO_4 , or K_2HPO_4 .

11. The surgical cement of claim 9 wherein said soluble pH adjusting reagent is premixed with said cementing powder and said setting reagent.

12. The surgical cement of claim 9 wherein said soluble pH adjusting reagent is dissolved in said aqueous setting solution.

13. The surgical cement of claim 1 wherein the cementing powder further comprises up to approximately 5:1 by weight of filler to cementing powder.

///

///

///

///

///

///

14. The surgical cement of claim 13 wherein the filler is selected from the group consisting of tetracalcium phosphate, α -tricalcium phosphate, β -tricalcium phosphate, calcium phosphate apatite, octacalcium phosphate, dicalcium phosphate, calcium carbonate, calcium oxide, calcium hydroxide, calcium sulfate dihydrate, calcium sulfate hemihydrate, calcium sulfate anhydrous, calcium fluoride, calcium citrate, magnesium oxide, magnesium hydroxide, and collagen.

15. The surgical cement of claim 13 wherein said filler is a powder of granule form having a particle size ranging from 1 micron to 20 mesh.

16. The surgical cement of claim 1 further comprising up to approximately 20% of an antibiotic.

17. The surgical cement of claim 1 further comprising up to approximately 10% bone growth protein.

18. A process for forming the surgical cement of claim 1 in which the setting reagent and pH adjusting reagents are dissolved in aqueous solution consisting of water or saline water to form an aqueous setting solution prior to intermixing with the cementing powder to form a paste capable of hardening into a cement.

///

///

19. A process for forming the surgical cement of claim 1 in which the setting reagent and pH adjusting reagents are premixed with the cementing powder prior to its intermixture with the aqueous solution consisting of water or saline water to form a paste capable of hardening into
5 a cement.

20. A kit for making a surgical cement for orthopedic, dental, and maxillofacial applications comprising:

a cementing powder consisting of calcium alkali phosphate ceramics; and

5 a setting reagent;

said cementing powder and said setting reagent, when admixed with sufficient aqueous solution forms a cementitious paste, which after setting, will attain a pH of at least 7.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 93/11071

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61L25/00 A61L27/00 A61K6/033

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61L A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| X | US,A,5 149 368 (SUNG-TSUEN LIU ET AL.) 22 September 1992 see examples 1-5 --- | 1 |
| A | EP,A,0 538 914 (NITTA GELATIN INC.) 28 April 1993 see claims --- | 1 |
| A | WO,A,90 00892 (NITTA GELATIN INC.) 8 February 1990 see examples 1-4 --- | 1 |
| A | EP,A,0 520 690 (NITTA GELATIN INC.) 30 December 1992 see claims --- | 1 |
| | -/-- | |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

15 July 1994

Date of mailing of the international search report

29. 07. 94

Name and mailing address of the ISA

European Patent Office, P.O. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

ESPINOSA, M

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 93/11071

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| A | EP,A,0 324 425 (ASAHI KOGAKU KOGYO KK) 19 July 1989 see examples 1-6 --- | 1 |
| A | US,A,5 218 035 (SUNG-TSUEN LIU.) 8 June 1993 see claims --- | 1 |
| E | US,A,5 262 166 (SUNG-TSUEN, LIU ET AL.) 16 November 1993 see examples ----- | 1-13 |

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 93/11071

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| US-A-5149368 | 22-09-92 | NONE | |
| EP-A-0538914 | 28-04-93 | DE-D- 68915265 | 16-06-94 |
| | | EP-A- 0389629 | 03-10-90 |
| | | EP-A- 0538913 | 28-04-93 |
| | | WO-A- 9001341 | 22-02-90 |
| | | US-A- 5223029 | 29-06-93 |
| WO-A-9000892 | 08-02-90 | JP-A- 2034172 | 05-02-90 |
| | | DE-D- 68912302 | 24-02-94 |
| | | EP-A- 0386253 | 12-09-90 |
| | | US-A- 5238491 | 24-08-93 |
| EP-A-0520690 | 30-12-92 | JP-A- 5168692 | 02-07-93 |
| EP-A-0324425 | 19-07-89 | JP-A- 2001285 | 05-01-90 |
| | | JP-B- 5034987 | 25-05-93 |
| | | US-A- 5137534 | 11-08-92 |
| US-A-5218035 | 08-06-93 | NONE | |
| US-A-5262166 | 16-11-93 | NONE | |